In a shocking move, Organon CEO Kevin Ali has stepped down from his position as the company embarks on a search for a new leader. The departure comes as Organon faces growing scrutiny over "improper" sales practices related to its birth control implant, Nexplanon. An internal investigation has uncovered concerns about the company's tactics, sparking questions about the integrity of its sales and marketing efforts. As the pharmaceutical industry grapples with the implications of this scandal, investors and regulators will be watching closely to see how Organon navigates this crisis and whether its new CEO can restore trust in the company.
Organon CEO exits, company goes on hunt for successor as internal probe turns up 'improper' Nexplanon sales tactics Fierce Pharma
